[1]韋 奇,高振軒,高 陽,等.他汀類藥物聯合抗血小板藥物降低冠狀動脈搭橋術后血管再狹窄的研究[J].醫學信息,2019,(20):40-44.[doi:10.3969/j.issn.1006-1959.2019.20.012]
 WEI Qi,GAO Zhen-xuan,GAO Yang,et al.Study of Statins Combined with Antiplatelet Drugs to Reduce Vascular Restenosis after Coronary Artery Bypass Grafting[J].Medical Information,2019,(20):40-44.[doi:10.3969/j.issn.1006-1959.2019.20.012]
點擊復制

他汀類藥物聯合抗血小板藥物降低冠狀動脈搭橋術后血管再狹窄的研究()
分享到:

醫學信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期數:
2019年20期
頁碼:
40-44
欄目:
綜述
出版日期:
2019-10-15

文章信息/Info

Title:
Study of Statins Combined with Antiplatelet Drugs to Reduce Vascular Restenosis after Coronary Artery Bypass Grafting
文章編號:
1006-1959(2019)20-0040-05
作者:
韋 奇1高振軒1高 陽1任京媛2
(1.首都醫科大學2015級臨床醫學專業,北京 100069;2.首都醫科大學附屬北京安貞醫院高血壓科,北京 100025)
Author(s):
WEI Qi1GAO Zhen-xuan1GAO Yang1REN Jing-yuan2
(1.Major in Clinical Medicine,Grade 2015,Capital Medical University,Beijing 100069,China;2.Department of Hypertension,Beijing Anzhen Hospital,Capital Medical University,Beijing 100025,China)
關鍵詞:
冠狀動脈旁路移植術血管再狹窄抗血小板藥物他汀類藥物
Keywords:
Coronary artery bypass graftingVascular restenosisAntiplatelet drugsStatins
分類號:
R543
DOI:
10.3969/j.issn.1006-1959.2019.20.012
文獻標志碼:
A
摘要:
冠狀動脈旁路移植術(CABG)是治療冠心病有效手段之一,但是其術后易發生橋靜脈再狹窄甚至閉塞,發生復發性心絞痛、心肌梗死以及再次血運重建的風險增加。抗血小板藥物和他汀類藥物是臨床提高橋血管通暢率的常用藥物,抗血小板藥物能減少早期的血栓形成,他汀類藥物能夠延緩中期的內膜增厚和晚期的粥樣斑塊的形成。本文就聯合使用抗血小板藥物和他汀類藥物降低CABG術后血管再狹窄的研究作一綜述,并對綜合治療CABG術后血管再狹窄的方法進行展望。
Abstract:
Coronary artery bypass grafting (CABG) is one of the effective methods for the treatment of coronary heart disease, but it is prone to restenosis or even occlusion of the bridge vein, and the risk of recurrent angina pectoris, myocardial infarction and revascularization is increased. Antiplatelet drugs and statins are commonly used drugs to improve the patency rate of bridge blood vessels. Antiplatelet drugs can reduce early thrombosis. Statins can delay the formation of metaphase intimal thickening and advanced atheroma. This article reviews the use of antiplatelet drugs and statins to reduce vascular restenosis after CABG, and prospects for the comprehensive treatment of vascular restenosis after CABG.

參考文獻/References:

[1]Kim LK,Looser P,Swaminathan RV,et al.Outcomes in patients undergoing coronary artery bypass graft surgery in the United States based on hospital volume,2007 to 2011[J].J Thorac Cardiovasc Surg,2016,151(6):1686-1692. [2]Tranbaugh RF,Schwann TA,Swistel DG,et al.Coronary Artery Bypass Graft Surgery Usingthe Radial Artery,Right Internal Thoracic Artery,orSaphenous Vein as theSecondConduit[J].Annals of Thoracic Surgery,2017,104(2):S0003497516316198. [3]Yamasaki M,Deb S,Tsubota H,et al.Comparison of Radial Artery and Saphenous Vein Graft Stenosis More Than 5 Years After Coronary Artery Bypass Grafting[J].Ann Thorac Surg,2016,102(3):712-719. [4]YamaneY,Uchida N,Okubo S,et al.Impact of the size mismatch between saphenous vein graft and coronary artery on graft patency[J].General Thoracic&Cardiovascular Surgery,2016,65(1):1-7. [5]劉巍,周玉杰,劉字揚,等.靜脈橋病變的介入治療及臨床預后的觀察[A]//第七屆北京五洲心血管病研討會論文集[C].首都醫科大學附屬北京安貞醫院,2013. [6]Harskamp RE,Lopes RD,Baisden CE,et al.Saphenous Vein Graft Failure After Coronary Artery Bypass Surgery[J].Annals of surgery,2013,257(5):824-833. [7]Kim FY,Marhefka G,Ruggiero NJ,et al.Saphenous Vein Graft Disease:,Review of Pathophysiology, Prevention,and Treatment[J].Cardiology in Review,2013,21(2):101-109. [8]Tseng CN,Karl?觟f E,Chang YT,et al.Contribution of Endothelial Injury and Inflammation in Early Phase to Vein Graft Failure:The Causal Factors Impact on the Development of Intimal Hyperplasia in Murine Models[J].PloS One,2014,9(6):e98904. [9]Longchamp A,Alonso F,Dubuis C,et al.The use of external mesh reinforcement to reduce intimal hyperplasia and preserve the structure of human saphenous veins[J].Biomaterials,2014,35(9):2588-2599. [10]Taggart DP,Ben Gal Y,Lees B,et al.A Randomized Trial of External Stenting for Saphenous Vein Grafts in Coronary Artery Bypass Grafting[J].The Annals of Thoracic Surgery,2015,99(6):2039-2045. [11]Pere kB,Malinska A,Misterski M,et al.Preexisting high expression of matrix metalloproteinase-2 in tunica media of saphenous vein conduits is associated with unfavorable long-term outcomes after coronary artery bypass grafting[J].Bio Med Research International,2013(3):730721. [12]Ezhov MV,Afanasieva OI,Il"Ina LN,et al.Association of lipoprotein(a)level with short- and long-term outcomes after CABG:The role of lipoprotein apheresis[J].Atherosclerosis Supplements,2017(30):187-192. [13]Yahagi K,Kolodgie FD,Fran kD,et al.Pathophysiologyof native coronary,vein graft,and in-stent atherosclerosis[J].Nature Reviews Cardiology,2015,13(2):79. [14]Yanagawa B,Algarni KD,Khaled D,et al.Clinical, biochemical, and genetic predictors of coronary artery bypass graft failure[J].Journal of Thoracic&Cardiovascular Surgery,2014,148(2):515-520. [15]Balogh E,Darago A,Csapo K,et al.Homocysteine increases the risk of long term coronary artery saphenous venous graft progression[J].European Heart Journal,2013,34(1):3115. [16]Wang B,Yamamoto MH,Nand P,et al.Long-term changes in plaque burden and vessel remodeling in saphenous vein grafts:insights from serial intravascular ultrasound[J].Coronary artery disease,2016,27(6):523-527. [17]程斌,穆軍升.冠狀動脈旁路移植手術后的血管用藥[J].中華胸心血管外科雜志,2013,29(5):311-314. [18]Jing-Jing SU,Liu HY.Research Progress in Saphenous Vein Graft Restenosis after Coronary Artery Bypass Grafting[J].Chinese Journal of Clinical Thoracic&Cardiovascular Surgery,2013. [19]Hlatky MA,Solomon MD,Shilane D,et al.Use of Medications for Secondary Prevention After Coronary Bypass Surgery Compared With Percutaneous Coronary Intervention[J].Journal of the American College of Cardiology,2013,61(3):295-301. [20]Hage A,Voisine P,Erthal F,et al.Eight-Year Follow-up of the Clopidogrel After Surgery for Coronary Artery Disease(CASCADE)Trial[J].The Journal of Thoracic and Cardiovascular Surgery, 2018,155(1):212-222. [21]Deo SV,Dunlay SM,Shah IK,et al.Dual Anti-platelet Therapy After Coronary Artery Bypass Grafting:Is There Any Benefit?A Systematic Review and Meta-Analysis[J].Journal of Cardiac Surgery,2013,28(2):109-116. [22]Ebrahimi R,Gupta S,Carr BM,et al.Comparison of Outcomes and Costs Associated with Aspirin+/- Clopidogrel after Coronary Artery Bypass Grafting[J].American Journal of Cardiology,2018,121(6):709-714. [23]Levine GN,Glenn N,Bates ER,et al.2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease[J].J Thorac Cardiovasc Surg,2016,152(5):1243-1275. [24]Poston RS,Gu J,Brown M,et al.Endothelial injury and acquired aspirin resistance as promoters of regional thrombin formation and early vein graft failure after coronary artery bypass grafting[J].Journal of Thoracic&Cardiovascular Surgery,2006,131(1):122-130. [25]Floyd CN,Ferro A.Mechanisms of aspirin resistance[J].Pharmacology and Therapeutics,2014,141(1):69-78. [26]王學忠,龔曉璇,朱甜甜,等.聯合氯吡格雷和阿司匹林抗血小板治療對非體外循環冠狀動脈旁路移植術后患者阿司匹林抵抗的影響[J].中國醫學科學院學報,2013,35(5):495-502. [27]吳文波,吳明營,周自強,等.阿司匹林劑量對非體外循環下冠狀動脈旁路移植術后獲得性阿司匹林抵抗的影響[J].中華臨床醫師雜志(電子版),2013,7(13):49-52. [28]Gasparovic H,Petricevic M,Kopjar T,et al Impact of dual antiplatelet therapy on outcomes among aspirin-resistant patients following coronary artery bypass grafting[J].Am J Cardiol,2014(113):1660-1667. [29]王秀珠,范國峰.經皮冠狀動脈介入治療術后抗血小板治療依從性調查分析[J].中國全科醫學,2010,13(31):3570-3571. [30]Nocerino AG,Achenbach S,Taylor AJ.Meta-analysis of effect of single versus dual antiplatelet therapy on early patency of bypass conduits after coronary artery bypass grafting[J].American Journal of Cardiology,2013,112(10):1576-1579. [31]Une D,Al-Atassi T,Kulik A,et al.Impact of clopidogrel plus aspirin versus aspirin alone on the progression of native coronary artery disease after bypass surgery: analysis from the Clopidogrel After Surgery for Coronary Artery Disease(CASCADE)randomized trial[J].Circulation,2014,130(1):12-18. [32]Ohman EM,Roe MT,Matthew T,et al.Clinically significant bleeding with low-dose rivaroxaban versus aspirin,in addition to P2Y12 inhibition,in acute coronary syndromes(GEMINI-ACS-1):a double-blind,multicentre,randomised trial[J].Lancet,2017,389(10081):1799-1808. [33]Yahagi K,Kolodgie FD,Otsuka F,et al.Pathophysiologyof native coronary,vein graft,and in-stent atherosclerosis[J].Nature Reviews Cardiology,2016,13(2):79-98. [34]Kang S,Liu Y,Liu XB.Effects of Aggressive Statin Therapy on Patients With Coronary Saphenous Vein Bypass Grafts:A Systematic Review and Meta-Analysis of Randomized,Controlled Trials[J].Clinical Therapeutics,2013,35(8):1125-1136. [35]Lazar HL.Role of statin therapy in the coronary bypass patient[J].Annals of Thoracic Surgery,2004,78(2):730-740. [36]Shah SJ,Waters DD,Barter P,et al.Intensive Lipid-Lowering With Atorvastatin for Secondary Prevention in Patients After Coronary Artery Bypass Surgery[J].Journal of the American College of Cardiology,2008,51(20):1938-1943. [37]Kulik A,Abreu AM,Boronat V,et al.Intensive versus moderate atorvastatin therapy and one-year graft patency after CABG:Rationale and design of the ACTIVE(Aggressive Cholesterol Therapy to Inhibit Vein Graft Events)randomized controlled trial(NCT01528709)[J].Contemporary Clinical Trials,2017(59):98-104. [38]程斌,穆軍升,張健群,等.冠狀動脈旁路移植術后使用負荷劑量他汀類藥物中長期療效的Meta分析[J].中華胸心血管外科雜志,2015,31(11):679-682,701. [39]Musial J,Undas A,Undas R,et al.Treatment with simvastatin and low-dose aspirin depresses thrombin generation in patients with coronary heart disease and borderline-high cholesterol levels[J].Thrombosis&Haemostasis,2001,85(2):221-225. [40]Xianghua F,Qian W,Yanbo W,et al.Influence on the platelet function of different statins combined with loading dose clopidogrel in patients with acute coronary syndrome[J].Heart,2010,96(3):A194-A195. [41]Nakamura K,Masuda H,Kariyazono H,et al.Effects of atorvastatin and aspirin combined therapy on inflammatory responses in patients undergoing coronary artery bypass grafting[J].Cytokine,2006,36(5-6):201-210. [42]Gupta RK,Bapuraj JR.Prognostic indices for cerebral venous thrombosis on CT perfusion:A prospective study[J].European Journal of Radiology,2014,83(1):185-190. [43]何中伏,李國瑞,段憲云.阿司匹林聯合他汀類藥物治療腦血栓的療效及對頸動脈斑塊的影響分析[J].中國合理用藥探索,2017,14(7):13-15,19. [44]吳菁華.他汀類聯合心血管藥物治療心血管疾病的臨床效果分析[J].當代醫學,2014(3):151-152. [45]耿凡龍,張霞.強化他汀聯用抗血小板藥物對支架植入術后再狹窄防治效果的觀察[J].中西醫結合心血管病電子雜志,2019,7(1):61-62.

相似文獻/References:

[1]馬洪俊.冠狀動脈左主干病變的治療研究[J].醫學信息,2019,(14):42.[doi:10.3969/j.issn.1006-1959.2019.14.015]
 MA Hong-jun.Study on the Treatment of Left Main Coronary Artery Disease[J].Medical Information,2019,(20):42.[doi:10.3969/j.issn.1006-1959.2019.14.015]

更新日期/Last Update: 2019-10-15
重庆时时开奖号码k线图